We are live on ! Find out more
VRNA

Verona Pharma
VRNA

Delisted

VRNA was delisted on the 6th of October, 2025.

Back to rankings

14 hedge funds and large institutions have $33.7M invested in Verona Pharma in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

26% more capital invested

Capital invested by funds: $26.8M → $33.7M (+$6.89M)

8% more funds holding

Funds holding: 13 → 14 (+1)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.01% less ownership

Funds ownership: 5.57% → 5.55% (-0.01%)

Holders
14
Holders Change
+1
Holders Change %
+7.69%
% of All Funds
0.28%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
2
Increased
3
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WS
Wedbush Securities
California
+$222K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$67.2K
3
Renaissance Technologies
Renaissance Technologies
New York
+$54.6K
4
UBS Group
UBS Group
Switzerland
+$39K
5
Deutsche Bank
Deutsche Bank
Germany
+$297

Top Sellers

Rank Fund Capital Flow
1
PC
Polar Capital
United Kingdom
-$457K

VRNA Hedge Fund Activity: Q4 2019 in Review

14 of the 5,079 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q4 2019, worth a combined $33.7M — up 26% from $26.8M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new VRNA positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Wedbush Securities, adding an estimated $222K. The largest seller was Polar Capital, exiting entirely with an estimated $457K sold.

  • 14 institutional investors held Verona Pharma (VRNA) as of Q4 2019, up from 13 in Q3 2019.
  • Funds reported $33.7M of Verona Pharma stock for Q4 2019, up 26% quarter-over-quarter.
  • 2 funds opened new Verona Pharma positions in Q4 2019 and 1 closed out, a net change of +1 holder.
  • The largest Verona Pharma buyer in Q4 2019 was Wedbush Securities, an estimated $222K added.
  • The largest Verona Pharma seller in Q4 2019 was Polar Capital, an estimated $457K sold.

Based on aggregated 13F filings for Q4 2019.